Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - AVANT Immunotherapeutics (NasdaqNM:AVAN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | Msgs | Insider | Options | Reports
Location
119 Fourth Avenue
Needham, MA 02494
Phone: (781) 433-0771
Fax: (781) 433-0262
Email: info@avantimmune.com
Employees (last reported count): 66
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 13%
·Over the last 6 months:
 · one insider buy; 1,000  shares
·Institutional: 28% (32% of float)
(91 institutions)
·Net Inst. Buying: 453.0K shares (+2.75%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
AVANT Immunotherapeutics, Inc. is a biopharmaceutical company that uses novel applications of immunology to prevent and treat diseases caused by both the enemy within (autoimmune diseases, cardiovascular diseases and inflammation) and the enemy without (infectious diseases and organ transplant rejection). The Company's most advanced therapeutic program focuses on compounds with the potential to inhibit inappropriate activation of the complement cascade, a vital part of the body's immune defense system. AVANT is also developing a portfolio of oral vaccines aimed at protecting travelers from diseases endemic in developing areas, as well as a proprietary therapeutic vaccine for the management of cholesterol. Through corporate collaborations, the Company is additionally developing a variety of infectious disease vaccines.
More from Market Guide: Expanded Business Description

Financial Summary
AVANT Immunotherapeutics, Inc. is a biotechnology company engaged in the discovery, commercialization and development of products that harness the human immune response to prevent and treat diseases. For the six months ended 6/30/01, revenues totalled $1.7 million, up from $308 thousand. Net loss rose 100% to $9.7 million. Results reflect higher development and licensing agreement revenues, and increased R&D expenses related to clinical trials of CETi-1 and TP10.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

J. Barrie Ward, Ph.D., 62
Chairman
--  --  
Una Ryan, Ph.D, 59
Pres, CEO, Chief Operating Officer, Director
$335K--  
Avery Catlin, 52
CFO, Sr. VP
204K--  
Henry Marsh, Jr., Ph.D, 51
VP, Research
172K$8.1K
Alistair Wheeler, M.D., 42
VP, Medical Affairs
167K52.6K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AVANAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$3.281
Recent Price$3.53 
52-Week High
on 7-Sep-2000
$12.375
Beta0.56 
Daily Volume (3-month avg)223.9K
Daily Volume (10-day avg)135.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-64.4%
52-Week Change
relative to S&P500
-52.2%
Share-Related Items
Market Capitalization$202.6M
Shares Outstanding57.4M
Float49.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.78 
Earnings (ttm)-$0.48 
Earnings (mrq)-$0.10 
Sales (ttm)$0.04 
Cash (mrq)$0.71 
Valuation Ratios
Price/Book (mrq)4.53 
Price/EarningsN/A 
Price/Sales (ttm)92.56 
Income Statements
Sales (ttm)$2.14M
EBITDA (ttm)-$28.4M
Income available to common (ttm)-$26.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-53.53%
Return on Equity (ttm)-62.74%
Financial Strength
Current Ratio (mrq)8.19 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$40.7M
Short Interest
As of 8-Aug-2001
Shares Short706.0K
Percent of Float1.4%
Shares Short
(Prior Month)
747.0K
Short Ratio3.03 
Daily Volume233.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.